Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

키워드

참고문헌 (42)

1. Takeda H, "Genetic basis of hepatitis virus-associated hepatocellular carcinoma : linkage between infection, inflammation, and tumorigenesis", J Gastroenterol, 52, pp.26~38 (2017)
2. Martel-Laferrière V, "Hepatitis C directacting antiviral agents : changing the paradigm of hepatitis C treatment in HIV-infected patients", J Clin Gastroenterol, 48, pp.106~112 (2014)
3. Wang LS, "Hepatitis C-A clinical review", J Med Virol, 88, pp.1844~1855 (2016)
4. van der Meer AJ, "Reversion of disease manifestations after HCV eradication", J Hepatol, 65(1 Suppl), pp.S95~S108 (2016)
5. Gutierrez JA, "Interferon-free, direct-acting antiviral therapy for chronic hepatitis C", J Viral Hepat, 22, pp.861~870 (2015)
6. Jacobson IM, "The HCV treatment revolution continues: resistance considerations, pangenotypic efficacy, and advances in challenging populations", Gastroenterol Hepatol (N Y), 12(10 Suppl 4), pp.1~11 (2016)
7. Asselah T, "Interferon free therapy with direct acting antivirals for HCV", Liver Int, 33(Suppl 1), pp.93~104 (2013)
8. Fried MW, "Once-daily simeprevir(TMC435)with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C : the randomized PILLAR study", Hepatology, 58, pp.1918~1929 (2013)
9. Gane EJ, "Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C", N Engl J Med, 368, pp.34~44 (2013)
10. Kendler BS, "Carnitine : an overview of its role in preventive medicine", Prev Med, 15, pp.373~390 (1986)
11. Malaguarnera M, "Carnitine derivatives : clinical usefulness", Curr Opin Gastroenterol, 28, pp.166~176 (2012)
12. Thangasamy T, "Role of L-carnitine in the modulation of immune response in aged rats", Clin Chim Acta, 389, pp.19~24 (2008)
13. Campos Y, "Muscle carnitine deficiency and lipid storage myopathy in patients with mitochondrial myopathy", Muscle Nerve, 16, pp.778~781 (1993)
14. Nakanishi H, "L-carnitine reduces muscle cramps in patients with cirrhosis", Clin Gastroenterol Hepatol, 13, pp.1540~1543 (2015)
15. Shiraki M, "Carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients", Hepatol Res, 47, pp.321~327 (2017)
16. Cecere A, "Efficacy of L-carnitine in reducing hyperammonaemia and improving neuropsychological test performance in patients with hepatic cirrhosis:results of a randomised trial", Clin Drug Investig, 22(Suppl 1), pp.7~14 (2002)
17. Hurot JM, "Effects of L-carnitine supplementation in maintenance hemodialysis patients : a systematic review", J Am Soc Nephrol, 13, pp.708~714 (2002)
18. Weinhandl ED, "Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003", Am J Kidney Dis, 50, pp.803~812 (2007)
19. Matsumoto Y, "Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin", Blood Purif, 19, pp.24~32 (2001)
20. Sotirakopoulos N, "The influence of l-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD", Ren Fail, 24, pp.505~510 (2002)
21. Abdallah Y, "The role of poly(ADP-ribose)polymerase(PARP)in the autonomous proliferative response of endothelial cells to hypoxia", Cardiovasc Res, 73, pp.568~574 (2007)
22. Izgüt-Uysal VN, "Peritoneal macrophages function modulation by L-carnitine in aging rats", Aging Clin Exp Res, 16, pp.337~341 (2004)
23. Saluk-Juszczak J, "Lcarnitine modulates blood platelet oxidative stress", Cell Biol Toxicol, 26, pp.355~365 (2010)
24. Malaguarnera G, "Acetyl-L-carnitine supplementation during HCV therapy with pegylated interferon-α 2b plus ribavirin : effect on work performance; a randomized clinical trial", Hepat Mon, 14, pp.e11608~ (2014)
25. Tamura K, "MEGA6:molecular evolutionary genetics analysis version 6.0", Mol Biol Evol, 30, pp.2725~2729 (2013)
26. "The CONSORT flow diagram"[URL]
27. Editors of the Drafting Committee for Hepatitis Management Guidelines : The Japan Society of Hepatology, "Guidelines for the management of hepatitis C virus infection: first edition, May 2012, the Japan Society of Hepatology", Hepatol Res, 43, pp.1~34 (2013)
28. Ware JE Jr, "Practical implications of item response theory and computerized adaptive testing: a brief summary of ongoing studies of widely used headache impact scales", Med Care, 38(9 Suppl), pp.II73~II82 (2000)
29. Tokuda Y, "Assessing items on the SF-8 Japanese version for health-related quality of life : a psychometric analysis based on the nominal categories model of item response theory", Value Health, 12, pp.568~573 (2009)
30. De Franceschi L, "Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection : role of membrane oxidative damage", Hepatology, 31, pp.997~1004 (2000)
31. Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C : a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
32. Luca C, "Adverse reactions of different treatments in chronic hepatitis C", Rev Med Chir Soc Med Nat Iasi, 113, pp.991~995 (2009)
33. Russmann S, "Ribavirin-induced anemia : mechanisms, risk factors and related targets for future research", Curr Med Chem, 13, pp.3351~3357 (2006)
34. El-Beshlawy A, "Apoptosis in thalassemia major reduced by a butyrate derivative", Acta Haematol, 114, pp.155~159 (2005)
35. Yeşilipek MA, "Interferon-alpha therapy for refractory idiopathic thrombocytopenic purpura in children", Turk J Pediatr, 39, pp.173~176 (1997)
36. Palmieri L, "Protection of beta-thalassaemic erythrocytes from oxidative stress by propionyl carnitine", Int J Tissue React, 16, pp.121~129 (1994)
37. Tsukuda Y, "Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection", J Med Virol, 89, pp.857~866 (2017)
38. Tomassini V, "Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis : results of a pilot, randomised, double-blind, crossover trial", J Neurol Sci, 218, pp.103~108 (2004)
39. Maan R, "ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection", PLoS One, 10, pp.e0139317~ (2015)
40. Anty R, "Plasma carnitine is associated with fatigue in chronic hepatitis C but not in the irritable bowel syndrome", Aliment Pharmacol Ther, 33, pp.961~968 (2011)
41. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
42. Gane EJ, "Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen", Hepatology, 66, pp.1083~1089 (2017)

관련 논문AI추천